about the author

Kyle Blankenship

kyle@endpointsnews.com @ka_blankenship
Kyle Blankenship on LinkedIn

author articles

Glax­o­SmithK­line, Mer­ck KGaA of­fi­cial­ly call it quits on $4B part­ner­ship for flail­ing can­cer drug

4 years ago
R&D

A new­ly pri­vate No­var­tis part­ner bags a megaround on its first go to tur­bocharge CAR-T, cell ther­a­py pipeline

4 years ago
Financing

Mer­ck, wad­ing even fur­ther in­to rare dis­ease, inks $11.5B deal for Ac­celeron and its po­ten­tial PAH block­buster

4 years ago
Deals

Safe­ty fears force Pfiz­er to change piv­otal DMD gene ther­a­py tri­al pro­to­col

4 years ago
R&D
Cell/Gene Tx

Look­ing to rewrite the rules of drug li­cens­ing, start­up An­ji is on the hunt for 'dy­nam­ic eq­ui­ty' joint ven­tures

4 years ago
Financing
R&D

Mer­ck emerges as lead bid­der in po­ten­tial Ac­celeron buy­out with deal pos­si­ble this week — re­port

4 years ago
Deals
Pharma

Bio­haven turns out a dud in fa­tal neu­rode­gen­er­a­tive dis­ease, cast­ing doubt on drug's chances in ALS

4 years ago
R&D

New ARIA cas­es dog Bio­gen's Aduhelm launch in an­oth­er po­ten­tial blow to block­buster hopes — an­a­lyst

4 years ago
FDA+

The fire un­der Glax­o­SmithK­line's Em­ma Walm­s­ley grows as an­oth­er well-known ac­tivist in­vestor grabs its pitch­fork — ...

4 years ago
People
Pharma

Covid-19 roundup: Pfiz­er tees up 500M vac­cine dos­es for do­na­tion in ex­pand­ed US pact; Ear­ly remde­sivir helps stave ...

4 years ago
Coronavirus

FDA hands ac­cel­er­at­ed nod to Seagen, Gen­mab's so­lo ADC in cer­vi­cal can­cer, but com­bo stud­ies look even more promis­ing

4 years ago
FDA+

Fresh off Fer­Gene's melt­down, David Meek takes over at Mi­rati with lead KRAS drug rac­ing to an ap­proval

4 years ago
People

Mi­rati tri­umphs again in KRAS-mu­tat­ed lung can­cer with a close­ly watched FDA fil­ing now in the cards

4 years ago
R&D

The best of the rest: High­lights from the be­low-the-fold pre­sen­ta­tions at #ES­MO21

4 years ago
R&D

Mi­rati's KRAS drug looks like the ear­ly fa­vorite in colon can­cer with new da­ta, putting the pres­sure square on Am­gen

4 years ago
R&D

As­traZeneca, Dai­ichi Sanky­o's ADC En­her­tu blows away Roche's Kad­cy­la in sec­ond-line ad­vanced breast can­cer

4 years ago
R&D

Mer­ck flesh­es out Keytru­da win in first-line cer­vi­cal can­cer, adding more fire­pow­er to its ear­ly can­cer push

4 years ago
R&D

Mer­ck­'s Keytru­da un­corks full da­ta on lat­est ad­ju­vant win — this time in melanoma — adding bricks to ear­ly can­cer ...

4 years ago
R&D

EQRx, CStone un­furl full lung can­cer da­ta for PD-L1 drug in what the part­ners are call­ing a first

4 years ago
R&D

As­traZeneca touts Imfinzi im­munother­a­py com­bos for lung can­cer in push to dri­ve PD-L1 drug up­take

4 years ago
R&D

Chi­nese CAR-T play­er books a megaround to dri­ve bustling cell ther­a­py port­fo­lio through the clin­ic

4 years ago
Financing

Zymeworks squares up with Her­ceptin af­ter HER2 bis­pe­cif­ic aces mid-stage test in esophageal can­cer

4 years ago
R&D

Am­gen rolls out da­ta for KRAS in­hibitor com­bo study in col­orec­tal can­cer, hop­ing to move on from ug­ly ear­ly re­sults

4 years ago
R&D

Look­ing for the next mR­NA break­through, Mod­er­na taps Ab­Cellera in mys­te­ri­ous an­ti­body dis­cov­ery deal

4 years ago
Deals
Discovery
First page Previous page 3456789 Next page Last page
A service from the Financial Times